Mather Group LLC. Buys New Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Mather Group LLC. bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,872 shares of the biopharmaceutical company’s stock, valued at approximately $547,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Capital Advisors Ltd. LLC increased its holdings in shares of Gilead Sciences by 29.4% during the third quarter. Capital Advisors Ltd. LLC now owns 607 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 138 shares in the last quarter. Mastrapasqua Asset Management Inc. boosted its position in shares of Gilead Sciences by 4.5% during the third quarter. Mastrapasqua Asset Management Inc. now owns 3,494 shares of the biopharmaceutical company’s stock valued at $216,000 after buying an additional 150 shares during the last quarter. GHP Investment Advisors Inc. boosted its position in shares of Gilead Sciences by 1.7% during the third quarter. GHP Investment Advisors Inc. now owns 8,951 shares of the biopharmaceutical company’s stock valued at $552,000 after buying an additional 153 shares during the last quarter. JFS Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 68.1% during the third quarter. JFS Wealth Advisors LLC now owns 400 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 162 shares during the last quarter. Finally, Global Retirement Partners LLC boosted its position in shares of Gilead Sciences by 7.4% during the third quarter. Global Retirement Partners LLC now owns 2,437 shares of the biopharmaceutical company’s stock valued at $191,000 after buying an additional 168 shares during the last quarter. Institutional investors own 78.72% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the topic of several recent analyst reports. Piper Sandler increased their price objective on Gilead Sciences from $111.00 to $112.00 and gave the company an “overweight” rating in a research report on Friday, February 3rd. Barclays raised their target price on Gilead Sciences from $76.00 to $84.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 18th. Robert W. Baird raised their target price on Gilead Sciences from $69.00 to $80.00 in a research report on Friday, February 3rd. Mizuho raised their target price on Gilead Sciences from $88.00 to $101.00 and gave the stock a “buy” rating in a research report on Tuesday, February 14th. Finally, Morgan Stanley raised their target price on Gilead Sciences from $80.00 to $81.00 and gave the stock an “equal weight” rating in a research report on Friday, February 3rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $89.40.

Gilead Sciences Stock Up 1.3 %

Shares of GILD opened at $79.77 on Wednesday. The company has a current ratio of 1.29, a quick ratio of 1.15 and a debt-to-equity ratio of 1.14. Gilead Sciences, Inc. has a 12-month low of $57.17 and a 12-month high of $89.74. The business’s 50 day moving average is $83.65 and its 200 day moving average is $78.28. The company has a market capitalization of $99.48 billion, a PE ratio of 21.85, a price-to-earnings-growth ratio of 0.95 and a beta of 0.38.

Gilead Sciences (NASDAQ:GILD – Get Rating) last released its quarterly earnings data on Thursday, February 2nd. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.50 by $0.17. Gilead Sciences had a return on equity of 44.46% and a net margin of 16.83%. The business had revenue of $7.39 billion for the quarter, compared to the consensus estimate of $6.63 billion. During the same quarter in the previous year, the company posted $0.69 EPS. The company’s revenue was up 2.0% compared to the same quarter last year. Research analysts expect that Gilead Sciences, Inc. will post 6.84 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 30th. Shareholders of record on Wednesday, March 15th will be paid a $0.75 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.73. The ex-dividend date is Tuesday, March 14th. This represents a $3.00 dividend on an annualized basis and a yield of 3.76%. Gilead Sciences’s payout ratio is presently 80.00%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 12,984 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $79.96, for a total value of $1,038,200.64. Following the sale, the insider now owns 70,130 shares of the company’s stock, valued at approximately $5,607,594.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

(Get Rating)

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.